InspireMD (NSPR) 10-K 16 Feb 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 15, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	1,433,607
Document Type	10-K
Trading Symbol	NSPR
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 2,901,719
Entity Common Stock, Shares Outstanding		1,472,606
Trading symbol	NSPR
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 7,516	$ 3,257
Accounts receivable:
Trade, net	356	405
Other	157	142
Prepaid expenses	65	75
Inventory	500	753
TOTAL CURRENT ASSETS	8,594	4,632
NON-CURRENT ASSETS:
Property, plant and equipment, net	379	472
Fund in respect of employee rights upon retirement	399	502
Royalties buyout	38	87
TOTAL NON-CURRENT ASSETS	816	1,061
TOTAL ASSETS	9,410	5,693
CURRENT LIABILITIES:
Current maturity of long-term loan	2,680	4,149
Accounts payable and accruals:
Trade	618	512
Other	1,447	2,006
Advanced payment from customers	33	167
TOTAL CURRENT LIABILITIES	4,778	6,834
LONG-TERM LIABILITIES:
Liability for employees rights upon retirement	587	706
Long-term loan		1,099
TOTAL LONG-TERM LIABILITIES	587	1,805
COMMITMENTS AND CONTINGENT LIABILITIES (Note 9)
TOTAL LIABILITIES	5,365	8,639
EQUITY (CAPITAL DEFICIENCY):
Common stock, par value $0.0001 per share; 150,000,000 and 50,000,000 shares authorized at December 31, 2016 and 2015, respectively; 1,475,318 and 314,065 shares issued and outstanding at December 31, 2016 and 2015, respectively
Preferred shares, par value $0.0001 per share; 5,000,000 shares authorized at December 31, 2016 and 2015, respectively; 311,521 and 0 shares issued and outstanding at December 31, 2016 and 2015, respectively
Additional paid-in capital	135,959	120,050
Accumulated deficit	(131,914)	(122,996)
Total equity (capital deficiency)	4,045	(2,946)
Total liabilities and equity (net of capital deficiency)	$ 9,410	$ 5,693

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, per share	$ 0.0001	$ 0.0001
Common stock shares, authorized	150,000,000	50,000,000
Common stock shares, issued	1,475,318	314,065
Common stock shares, outstanding	1,475,318	314,065
Preferred stock, per share	$ 0.0001	$ 0.0001
Preferred stock shares, authorized	5,000,000	5,000,000
Preferred stock shares, issued	311,521	0
Preferred stock shares, outstanding	311,521	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
REVENUES	$ 1,894	$ 2,310
COST OF REVENUES	1,792	2,606
GROSS PROFIT (LOSS)	102	(296)
OPERATING EXPENSES:
Research and development	1,291	3,642
Selling and marketing	1,459	3,178
General and administrative	5,000	6,387
Restructuring and impairment		982
Total operating expenses	7,750	14,189
LOSS FROM OPERATIONS	(7,648)	(14,485)
FINANCIAL EXPENSES, net:
Interest expenses	721	1,036
Other financial expenses	91	60
Total financial expenses	812	1,096
LOSS BEFORE TAX EXPENSES	(8,460)	(15,581)
TAX EXPENSES	1	4
NET LOSS	$ (8,461)	$ (15,585)
NET LOSS PER SHARE - basic and diluted	$ (5.93)	$ (55.85)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted	1,425,617	279,055

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity (Capital Deficiency) - USD ($) $ in Thousands	Common Stock		Preferred Stock		Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2014		[1]			$ 104,624	$ (107,411)	$ (2,787)
Balance, shares at Dec. 31, 2014	170,710
Net loss						(15,585)	(15,585)
Issuance of common stock, preferred shares and warrants, net of issuance costs		[1]			12,432		12,432
Issuance of common stock, preferred shares and warrants, net of issuance costs, shares	137,479
Share-based compensation related to restricted stock award, net of forfeitures					1,286		1,286
Share-based compensation related to restricted stock award, net of forfeitures, shares	7,460
Share-based compensation related to stock options award					1,821		1,821
Taxes withheld in respect of share issuance		[1]			(113)		(113)
Taxes withheld in respect of share issuance, shares	(1,584)
Warrants granted to lender in a debt modification
Balance at Dec. 31, 2015		[1]			120,050	(122,996)	(2,946)
Balance, shares at Dec. 31, 2015	314,065
Net loss						(8,461)	(8,461)
Issuance of common stock, preferred shares and warrants, net of issuance costs				[1]	14,365		14,365
Issuance of common stock, preferred shares and warrants, net of issuance costs, shares	117,327		442,424
Share-based compensation related to restricted stock award, net of forfeitures					84		84
Share-based compensation related to restricted stock award, net of forfeitures, shares	128,559
Share-based compensation related to stock options award					894		894
Taxes withheld in respect of share issuance		[1]			(14)		(14)
Taxes withheld in respect of share issuance, shares	(1,262)
Cumulative effect adjustment related to adoption of share-based compensation standard (ASU 2016-09)					457	(457)
Conversion of preferred shares to common shares		[1]		[1]
Conversion of preferred shares to common shares, shares	916,321		(130,903)
Warrants granted to lender in a debt modification					123		123
Exercise of options by employee and non-employee		[1]
Exercise of options by employee and non-employee, shares	300
Issuance of shares for options cancelled		[1]
Issuance of shares for options cancelled, shares	8
Balance at Dec. 31, 2016		[1]		[1]	$ 135,959	$ (131,914)	$ 4,045
Balance, shares at Dec. 31, 2016	1,475,318		311,521
[1]	Represents an amount less than $1

Consolidated Statements of Cha6

Consolidated Statements of Changes in Equity (Capital Deficiency) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 1,966	$ 1,315
Restricted stock award, shares	1,266	406

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (8,461)	$ (15,585)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	191	241
Impairment of royalties buyout		576	[1]
Loss from sale of property, plant and equipment		14
Change in liability for employees rights upon retirement	(119)	19
Financial expenses	222	249
Share-based compensation expenses	978	3,107
Loss (gains) on amounts funded in respect of employee rights upon retirement, net	(16)	3
Changes in operating asset and liability items:
Decrease in prepaid expenses	10	141
Decrease in trade receivables	49	230
Decrease (increase) in other receivables	(15)	217
Decrease in inventory	253	1,171
(Decrease) increase in trade payables	106	(397)
Decrease in other payable and advanced payment from customers	(693)	(1,582)
Net cash used in operating activities	(7,495)	(11,596)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(49)	(16)
Amounts funded in respect of employee rights upon retirement, net	119	(7)
Net cash used in investing activities	70	(23)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares and warrants, net of $1,966 and $1,315 issuance costs, respectively	14,365	12,432
Repayment of loan	(2,648)	(3,702)
Taxes withheld in respect of share issuance	(14)	(113)
Net cash provided by financing activities	11,703	8,617
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(19)	(41)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	4,259	(3,043)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	3,257	6,300
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	7,516	3,257
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Income taxes	6	13
Interest paid	399	863
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES:
Warrants granted to lender in a debt modification, see Note 7c	$ 123
[1]	During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents.

Consolidated Statements of Cas8

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Statement of Cash Flows [Abstract]
Issuance costs	$ 1,966	$ 1,315

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. In October 2014, the Company launched a limited market release of its carotid embolic prevention system (CGuard™ EPS), which combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. In January 2015, a new version of CGuard, with a rapid exchange delivery system, received CE mark approval in Europe and in September 2015, the Company announced the full market launch of CGuard EPS in Europe. The Company’s coronary products combining MicroNet and a bare-metal stent (MGuard Prime™ EPS) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Company markets its products through distributors in international markets, mainly in Europe and Latin America. b. Liquidity The Company has an accumulated deficit as of December 31, 2016, as well as a history of net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its products (primarily CGuard™ EPS) reach commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company only has sufficient resources to fund operations for a period of up to six months from the date of issuing these consolidated financial statements. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the continued commercialization of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, share based compensation and legal contingencies. b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates. c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation. d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents. e. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable are derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable- Trade”. f. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or market value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventories and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value. g. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements. h. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. i. Revenue recognition Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer and collection is reasonably assured. The Company recognizes revenue net of value added tax (VAT). j. Research and development costs Research and development costs are charged to the statement of operations as incurred. k. Share-based compensation Employee option awards are classified as equity awards and accounted for using the grant-date fair value method. The fair value of share-based awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period, net of estimated forfeitures. Until December 31, 2015, the Company estimated forfeitures based on historical experience and anticipated future conditions. Beginning on January 1, 2016, the Company adopted Accounting Standards Update (“ASU”) 2016-09 and and elected to account for forfeitures as they occur. See Note 2s4. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach. In addition, certain share-based awards of the Company are market and performance based and dependent upon achieving certain goals. With respect to performance based awards, the Company estimates the expected pre-vesting award probability that the performance conditions will be achieved. The Company only recognizes expense for those shares that are expected to vest. l. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses -net”. m. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. n. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $0.1 million and $0.2 million for the years ended December 31, 2016 and 2015, respectively. o. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock by the weighted average number of shares of common stock outstanding during the period. For the year ended December 31, 2016 the basic and diluted net loss per also included 602,614 weighted average shares of common stock issuable to holders of Series B Convertible Preferred Stock (since the conversion is based only on the passage of time – see Note 10a). The calculation of diluted net loss per share excludes potential share issuances of common stock upon the exercise of share options, warrants, restricted stocks and placement agent unit as the effect is anti-dilutive. The total number of shares of common stock related to outstanding options, warrants, restricted stocks and placement agent unit excluded from the calculations of diluted loss per share were 2,668,117 and 200,194 for the years ended December 31, 2016 and 2015, respectively. p. Segment reporting The Company has one operating and reportable segment. q. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. s. Recently adopted and issued accounting pronouncements 1) In April, 2015, the Financial Accounting Standards Board (“FASB”) ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” The new guidance requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The new guidance does not affect the recognition and measurement of debt issuance costs. The new guidance became effective during the first quarter of 2016 and was applied on a retrospective basis. As of December 31, 2016 and December 31, 2015, $35,000 and $85,000, respectively were deducted from the carrying value of the “Current maturity of loan” in the consolidated balance sheets. 2) In May 2014, the FASB issued Accounting Standards Codification (“ASC”) 606, Revenue from contracts with customers. The objective of the new revenue standard is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. The revenue standard contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services, based on a five step model that includes the identification of the contract with the customer and the performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the performance obligations in the contract and recognizing revenue when (or as) the entity satisfies a performance obligation. The revenue standard is effective for annual periods beginning on or after December 15, 2017. The Company expected that the adoption of this standard will not have a material impact on its consolidated financial statements. 3) On July 22, 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out and the retail inventory method are not impacted by the new guidance. The new guidance will be effective for public business entities in fiscal years beginning after December 15, 2016, including interim periods within those years. Prospective application is required. Early adoption is permitted as of the beginning of an interim or annual reporting period. The adoption of this standard is not expected to have a material impact on its consolidated financial statements. 4) In March 2016, the FASB issued ASU 2016-09 – Improvements to Employee Share Based Payment Accounting which simplifies certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. This ASU is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not yet been issued, and all amendments in the ASU that apply must be adopted in the same period. The Company adopted the update during the quarter ended December 31, 2016, and has retroactively applied the guidance effective as of January 1, 2016. The Company elected to account for forfeitures as they occur rather than estimate expected forfeitures which resulted in a cumulative-effect adjustment to retained earnings as of the beginning of the current period of $457,000. Certain amounts or ratios for 2016 interim periods have been restated to reflect the adoption of this new guidance. Adoption of this update does not affect the Company’s total equity or book value per share. 5) In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230) Restricted Cash”. The new guidance requires that the reconciliation of the beginning-of-period and end-of-period amounts shown in the statement of cash flows include restricted cash and restricted cash equivalents. If restricted cash is presented separately from cash and cash equivalents on the balance sheet, companies will be required to reconcile the amounts presented on the statement of cash flows to the amounts on the balance sheet. Companies will also need to disclose information about the nature of the restrictions. The guidance is effective for annual an interim reporting periods beginning after December 15, 2017, and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. 6) In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows Topic 230: Classification of Certain Cash Receipts and Cash Payments.” ASU No. 2016-15 issued guidance to clarify how certain cash receipts and cash payments should be presented in the statement of cash flows. ASU 2016-15 is effective for annual and interim reporting periods beginning on or after December 15, 2017 and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. 7) In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The new standard is effective for annual periods and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance. 8) In February 2016, the FASB issued ASU 2016-02, Leases, which requires to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The accounting standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company expected that the adoption of this standard will not have a material impact on its consolidated financial statements.

Restructuring and Impairment

Restructuring and Impairment	12 Months Ended
	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Restructuring and Impairment	NOTE 3 - RESTRUCTURING AND IMPAIRMENT Year ended December 31, 2015 ($ in thousands) Employee termination costs (1) 305 Lease settlement (2) 101 Total restructuring $ 406 Impairment of royalties buyout (3) 576 Total restructuring and impairment $ 982 During the first quarter of 2015, the board of directors approved to curtail developing and promoting our bare metal stent platform and implementing another cost reduction/focused spending plan. The plan has four components: (i) reducing headcount; (ii) limiting the focus of clinical and development expenses to only carotid and neurovascular products; (iii) limiting sales and marketing expenses primarily to those related to the CGuard EPS stent launch; and (iv) reducing all other expenses (including conferences, travel, promotional expenses, executive cash salaries, director cash fees, rent, etc.). (1) During the year ended December 31, 2015, the company incurred $305,000 of costs associated with reducing the Company’s headcount. (2) On November 5, 2015, the Company entered into a second amendment (the “Second Lease Amendment”) to the lease agreement for its facilities in the U.S. Pursuant to the Second Lease Amendment and effective January 1, 2016, the Company agreed to reduce its leased space and surrender the released premises. The Company also agreed to pay transaction costs and settlement amount of $101,000. (3) During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents. The Company values Level 3 Royalties buyout using an internally developed valuation model, whose inputs include future MGuard Prime EPS sales and the derived royalties payments.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	NOTE 4 - FAIR VALUE MEASURMENT Fair value of financial instruments The carrying amounts of financial instruments included in working capital approximate their fair value either because these amounts are presented at fair value or due to the relatively short-term maturities of such instruments. The fair value of the Loan (as defined in Note 7) approximated its carrying amount since it bears interest at rates that approximate current market rates.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	NOTE 5 - PROPERTY, PLANT AND EQUIPMENT a Composition of assets, grouped by major classifications, is as follows: December 31, 2016 2015 ($ in thousands) Cost: Computer equipment $ 227 $ 221 Office furniture and equipment 107 104 Machinery and equipment 1,001 961 Leasehold improvements 143 143 1,478 1,429 Less - accumulated depreciation and amortization (1,099 ) (957 ) Net carrying amount $ 379 $ 472 b. Depreciation and amortization expenses totaled approximately $142,000 and $152,000 for the years ended December 31, 2016 and 2015, respectively.

Liability for Employees Right U

Liability for Employees Right Upon Retirement	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Liability For Employees Right Upon Retirement	NOTE 6 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, some of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 relieve the Company from any future severance payments to these employees. The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses were approximately $130,000 and $211,000 for the years ended December 31, 2016 and 2015, respectively. Defined contribution plan expenses were approximately $157,000 and $213,000 for the years ended December 31, 2016 and 2015, respectively. The Company expects contribution plan expenses in 2017 to be approximately $198,000.

Loan

Loan	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Loan	NOTE 7 - loan 2013 Security and Loan Agreement a. Loan and Security Agreement On October 23, 2013, the Company and InspireMD Ltd. entered into a Loan and Security Agreement (the “Loan and Security Agreement”), pursuant to which a lender made a term loan to the Company and InspireMD Ltd. in the aggregate amount of $10 million (the “Loan”). The annual interest rate on the Loan is prime plus 4%, but shall not be reduced below 10.5%. Payments under the Loan and Security Agreement are for the interest portion only for 9 months, followed by 30 monthly payments of principal and interest through the scheduled maturity date on February 1, 2017. The Company is permitted to prepay all or a portion of the Loan. However, any prepayments of the Loan will be subject to a penalty of (i) 2%, if the prepayment occurs within 12 months of the Loan being requested by the Company and InspireMD Ltd. (the “Advance Date”), (ii) 1%, if the prepayment occurs between 12 and 24 months after the Advance Date, and (iii) 0.5%, if the prepayment occurs more than 24 months after the Advance Date. The Company and InspireMD Ltd. will also pay the lender an aggregate end of term charge (the “End of Term Charge”) of $500,000 when the Loan is paid in full or matures. In addition, upon the occurrence of a change in control, the Company shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and all unpaid lender’s fees and expenses accrued to the date of the repayment (including the End of Term Charge) together with the penalties stated above. b. Security Documents On October 23, 2013, InspireMD Ltd. issued the lender a Fixed Charge Debenture and a Floating Charge Debenture (collectively, the “Israeli Security Agreements”) in order to create a security interest in all the assets and property of InspireMD Ltd., securing the Company’s and InspireMD Ltd.’s obligations under the Loan and Security Agreement. In addition, on October 23, 2013 and November 8, 2013, the Company entered into Deposit Account Control Agreements with the lender and two banking institutions in the US (the “Deposit Account Control Agreements”) in order to perfect the lender’s security interest in the Company’s bank account. Pursuant to the Loan and Security Agreement, the Israeli Security Agreements and the Deposit Account Control Agreement, the Company’s obligations to the lender are secured by a first priority perfected security interest in all of the assets and properties of the Company and InspireMD Ltd., other than the intellectual property of the Company and InspireMD Ltd. The Company is required under the Loan and Security Agreement to maintain at all times in the bank accounts under the Deposit Account Control Agreements, cash and cash equivalents which may include cash collected from Accounts Receivable by Inspire M.D Ltd. and InspireM.D GmbH within the previous 7 days, and cash transferred to Inspire M.D Ltd. for the settlement of Permitted Indebtedness within the following 7 days, in each unrestricted and unencumbered, in an aggregate amount of at least the lesser of (a) an amount equal to one hundred percent of the then outstanding principal amount of the Term Loan Advance and (b) an amount equal to seventy-five percent of the aggregate amount of all of Borrower’s worldwide cash and cash equivalents. As of December 31, 2016, the future principal payments obligation for the Loan to be repaid in 2017 is $2,237,000. c. Loan Amendment On June 13, 2016, the Company amended (the “Amendment”) the Loan and Security Agreement, dated October 23, 2013, as amended, to provide that, among other things, the principal payment shall be suspended for a four month period beginning May 1, 2016, provided that the Company receives unrestricted and unencumbered net cash proceeds in an amount of at least $10 million from the sale of the Company’s equity securities with investors acceptable to the lender on or prior to June 30, 2016. The Amendment also modified the term loan maturity date under the Loan and security Agreement to (i) April 1, 2017, if the Company does not complete such sale of its equity securities and the lender does not waive such condition to complete such sale prior to June 30, 2016, or (ii) June 1, 2017, if the Company completes such sale of its equity securities, or if the lender waives such condition to complete such sale of its equity securities, prior to June 30, 2016. In addition, the Company agreed to increase the end of term charge from $500,000 to $520,000 on the earliest to occur of February 1, 2017, or when the loan is paid in full or matures. In connection with the Amendment, the Company and its subsidiary granted a security interest in their intellectual property to the lender (see Note 11b). In connection with the Amendment, the Company issued the lender warrants to purchase up to the number of shares of common stock equal to $182,399 divided by (i) the lowest effective price per share, determined on a common stock-equivalent basis, for which the Company’s equity securities are sold and issued by the Company in an equity financing in which the Company receives unrestricted aggregate gross cash proceeds of at least $7.5 million, subject to adjustment from time to time in accordance with the terms of the warrant agreement, or (ii) if such equity financing shall not have been consummated on or before July 30, 2016, or if, prior to the consummation of such equity financing, there shall be a transaction involving a change of control or a dissolution, liquidation or winding-up of the Company, then the closing price of a share of common stock on June 13, 2016, subject to adjustment thereafter from time to time in accordance with the terms of the warrant agreement. The warrants are immediately exercisable and have a five year term. The principal payments of May 1, 2016 and June 1, 2016 were suspended and although the July 2016 Offering (see Note 10a) had not closed prior to June 30, 2016, the lender agreed to waive the July 1, 2016 principal payment. Additionally, on July 6, 2016, the lender agreed to waive the August 1, 2016 principal payment, as well. The Loan under the Loan and Security Agreement, as amended by the Amendment, matures on June 1, 2017. The Company has concluded that the above changes to the terms of the Loan and security Agreement do not constitute a troubled debt restructuring as no concession has been granted. As such, the Company applied the guidance in ASC 470-50, Modifications and Extinguishments. The accounting treatment is determined by whether (1) the Investors remain the same and (2) the change in the debt terms is considered substantial. Since the lenders remained the same before and after the Amendment, the Company has made a quantitative test, in order to determine whether the Loan and security Agreement, as amended by the Amendment, is substantially different from the Loan and security Agreement prior to the Amendment became effective. According to ASC 470-50-40-10, from the debtor’s perspective, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different. Based on the accounting analysis performed, the Company concluded that the Loan and security Agreement, as amended by the Amendment, was not substantially different from the Loan and security Agreement prior to the Amendment becoming effective, and, as such, accounted for the Amendment as a modification. Accordingly, no gain or loss was recorded and a new effective interest rate was established based on the carrying value of the Loan and security Agreement prior to the Amendment became effective and the revised cash flows pursuant to the Loan and security Agreement, as amended by the Amendment, including the fair value of the warrants issued to the lender. Following the closing of the July 2016 Offering (see Note 10a), pursuant to the warrant agreement discussed above, the Company issued to the lender warrants to purchase 38,691 shares of common stock. The warrants are exercisable immediately and have a term of exercise of 5 years from the date of issuance and an exercise price of $4.71. Given the settlement mechanism described above, the warrants as of the Amendment date were classified as a liability and subsequently, upon closing of the July 2016 Offering, were reclassified to equity.

Related Parties Transactions

Related Parties Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Parties Transactions	NOTE 8 - RELATED PARTIES TRANSACTIONS a. Chief Executive Officer (“CEO”) On January 21, 2016, the Company and the Company’s former CEO entered into a fourth amendment to the former CEO’s Employment Agreement by and between the Company and the former CEO, in order to, among other things, (i) modify the term of the former CEO’s employment to end on the earlier of June 30, 2016 or the date upon which a new president and/or CEO (or executive performing a similar role) commences employment with the Company (or, if such individual is promoted internally, the date such individual is promoted to the position of president and/or chief executive officer); and (ii) provide that, during the remaining term of his employment, the former CEO will receive (A) 50% of his base salary in cash payments, for all days that the CEO works during the remaining term of his employment, at the monthly rate of $18,750, payable in accordance with the Company’s regular payroll practices, and (B) a lump-sum payment equivalent to 50% of the former CEO’s base salary through June 30, 2016, at the monthly rate of $18,750, payable within 20 business days from the earlier of (x) the Company raising an aggregate of $5 million from investors, or (y) June 30, 2016. On June 6, 2016, the former CEO resigned from all officer and director positions with the Company, and a new president and CEO commenced employment with the Company. On June 6, 2016, the Company appointed a new CEO, who was then the Company’s executive vice president and chief operating officer. In connection with his appointment, the Company and the CEO entered into a fourth amendment (the “Fourth Amendment”) to the employment agreement by and between the Company and the CEO, in order to, among other things, (i) change the title of his position to president and chief executive officer; (ii) modify the term of the CEO’s employment to (a) continue until May 31, 2017, with the CEO resigning as a member of the Board of Directors at the end of such term if requested by the Company and (b) provide that in the event that the term is not extended beyond May 31, 2017 by mutual agreement of the parties and the Company does not offer the CEO a position as CEO and/or chief operating officer on the same or more favorable terms with a base salary that is at least 10% greater than his current base salary, the CEO’s termination will be deemed a termination without cause; and (iii) amend the terms and conditions of the CEO’s compensation, as described below. Pursuant to the Fourth Amendment, for the period beginning on June 1, 2016 and ending on the earlier of (i) the closing of a transaction with investors where the Company raises an aggregate of $5 million (the “Financing”) and (ii) March 15, 2017, the CEO will receive 50% of his base salary in cash payments, payable in accordance with the Company’s regular payroll practices, with the remaining 50% of his base salary paid in a lump-sum payment on the first to occur of (a) the first payroll period that is on or after the 20th business day following the Financing or (b) March 15, 2017 (such earlier date, the “Reduction Amount Payment Date”). The Fourth Amendment also amends the terms of the CEO’s bonus compensation to provide that (i) the CEO is eligible to receive annual bonus compensation in an amount equal to 100% of his base salary upon the achievement of reasonable target objectives and performance goals as may be determined by the Board in consultation with the CEO and (ii) on the Reduction Amount Payment Date, the CEO will receive a lump-sum retention bonus in an amount equal to $106,458, subject to the CEO’s continued employment through such date. The Fourth Amendment further provides that on or within 20 business days of the closing of the Financing, the CEO will be granted, subject to approval of the Board of Directors and the CEO’s continued employment by the Company through the applicable grant date, (i) a nonqualified stock option relating to the number of shares of the Company’s common stock equal to 2% of the Company’s outstanding common stock on the date of the closing of the Financing (the “Financing Option”) and (ii) a restircted stock award equal to 2% of the Company’s outstanding common stock on the date of the closing of the Financing (the “Financing Restricted Stock Award”), in each case, subject to the terms and conditions of the Company’s 2013 Long-Term Incentive Plan and a nonqualified stock option agreement and a restricted stock award agreement to be entered into by the Company and the CEO. From the July 2016 Offering, the Company received more than an aggregate of $5 million, and, as such, on July 25, 2016, the CEO was granted the Financing Option to purchase 70,500 shares of the Company’s common stock at an exercise price of $4.75, which is equal to the closing fair market value of common stock on the date of grant, vesting on the first anniversary of the date of the grant, and on August 1, 2016, the CEO was granted the Financing Restricted Stock Award of 70,500 restricted shares of the Company’s common stock, vesting on the first anniversary of the date of the grant. In calculating the fair value of the above options the Company used the following assumptions: dividend yield of 0%; expected term of 5 years; expected volatility of 87.29%; and risk-free interest rate of 1.22%. The fair value of the above options, using the Black-Scholes option-pricing model, was approximately $0.2 million. The fair value of the above restricted shares of common stock, using the Black-Scholes option-pricing model, was approximately $0.3 million. b. On January 16, 2016, the Board of Directors appointed a new director and Vice Chairman of the Board, effective as of January 22, 2016, with a term expiring at the Company’s 2017 annual meeting of stockholders. On April 30, 2016, in connection with his appointment, the new director was granted an option to purchase 31,202 shares of the Company’s common stock at an exercise price equal to the closing fair market value of the common stock on the date of grant on April 30, 2016, subject to the terms and conditions of the the InspireMD, Inc. 2013 Long-Term Incentive Plan (the “2013 Plan”)and the 2011 UMBRELLA Option Plan. Options to purchase 7,801 shares of Common Stock vest and become exercisable immediately upon the time of grant, and, until all 31,202 options shall have vested, options to purchase 7,801 shares of common stock will vest and become exercisable each time upon (i) the Company raising at least $15 million through an equity offering; (ii) the Company’s market cap becoming equal to or greater than $25 million; (iii) the Company receiving research coverage by three new analysts at a leading investment bank; or (iv) the tripling of the Company’s market cap from the date of appointment. Any of the foregoing conditions, if achieved following the director’s appointment but prior to April 30, 2016, would have been deemed satisfied on the date of grant. However, in the event (i) of the director’s death or permanent disability, (ii) a change in control (as defined in the Plan) or (iii) if the director is asked to resign for any reason other than cause (as defined in the Company’s form of Nonqualified Stock Option Agreement under its Plan), the options shall vest immediately in full. The options have a term of 10 years from the date of grant and the exercise price may be paid in either cash or on a cashless basis. The fair value of options with market cap related conditions reflect the probability of achieving the respective condition, and are recognized through the date in which it is expected to be met. The fair value of such options was determined using the Monte-Carlo option-pricing model with the following primary assumptions: the probability to achieve various gross proceeds in future offerings, dividend yield of 0%; expected term of 10 years; expected volatility of 85.73%; and risk-free interest rate of 1.81%. The fair value of the above options with market conditions, using the Monte-Carlo option-pricing model, was approximately $96,000. The remaining tranches would vest upon achievment of performance conditions. Accordingly, the fair value of such options would be recognized based upon the number of options expected to vest and when the occurrence of the condition is considered probable. In calculating the fair value of the above options with performance conditions the Company used the following assumptions: dividend yield of 0%; expected term of 5.5 years; expected volatility of 85.81%; and risk-free interest rate of 1.25 %. The fair value of the above options with performance conditions, using the Black-Scholes option-pricing model, was approximately $66,000. c. On January 26, 2016 the Company entered into an option cancellation and release agreement with certain directors, the former CEO, the CEO who at the time was acting as the Company’s Chief Operating Officer and the Chief Financial Officer (“CFO”) (collectively “the Optionholders”), pursuant to which the parties agreed to cancel options to purchase an aggregate of 16,910 shares of common stock of the Company previously granted to each of the Optionholders. For accounting purposes, the cancellation was treated as a settlement for no consideration and accordingly all remaining unrecognized compensation cost amounting to approximately $800,000 was recognized. d. During the years ended December 31, 2016 and 2015, the Company granted stock options to directors to purchase a total of 134,232 and 5,555 shares of the Company’s common stock, respectively. The options have exercise prices of $3.04 - $12.50 and $42.50-$195.00, per share, respectively, which were the fair market value of the Company’s common stock on the date of each respective grant.Of the 134,232 options granted in 2016, 82,500 options are subject to a three-year vesting period with one-third of such awards vesting each year, 20,530 options were in lieu of cash compensation that was owed to them for their services as directors for the fourth quarter of 2015 and the first and second quarters of 2016 and are fully vested as of their grant date and the remaining options are subject to certain market and performance conditions. Of the 5,555 options granted in 2015, 4,320 options were in lieu of cash compensation that was owed to them for their services as directors for the third and fourth quarters of 2014 and the first through third quarter of 2015 and are fully vested as of their grant date and the remaining options are subject to a three-year vesting period, with one-third of such awards vesting each year. The fair value of the above options, using the Black-Scholes option-pricing model, was approximately $526,000 and $338,000, respectively. e. Balances with related parties: December 31, 2016 2015 ($ in thousands) Current liabilities: Other accounts payable $ 77 $ 132 f. Transactions with related parties: Year ended December 31, 2016 2015 ($ in thousands) Compensation expenses (including share based compensation) $ 1,499 $ 1,892

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	NOTE 9 - COMMITMENTS AND CONTINGENT LIABILITIES a. Lease commitments: 1) The Company has a lease agreement for its facilities in the U.S which expires in October 2017. The Subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2018 with an option to extend the agreement for two additional years until December 31, 2020 under the terms stipulated in the agreement. Rent expense included in the consolidated statements of operations totaled approximately $319,000 and $383,000 for the years ended December 31, 2016 and 2015, respectively. The rent expense for the year ended December 31, 2015 excludes $101,000, which is recorded under “Restructuring and impairment” in the consolidated statements of operations. See Note 3. As of December 31, 2016, the aggregate future minimum lease obligations for office rent under non-cancelable operating lease agreements are as follows: ($ in thousands) Year Ended December 31: 2017 $ 326 2018 276 $ 602 2) The Company leases its motor vehicles under operating lease agreements. As of December 31, 2016, the aggregate non-cancelable future minimum lease obligations for motor vehicles were approximately $6,000. b. Liens and pledges: The Company’s obligations under the Loan and Security Agreement were secured by the Israeli Security Agreements and the Deposit Account Control Agreements on all of the assets and properties of the Company and InspireMD Ltd., other than the intellectual property of the Company and InspireMD Ltd. See Note 7. c. Litigation: In December 2012, a former service provider of InspireMD GmbH filed a claim with the Labor Court in Buenos Aires, Argentina in the amount of $193,378 plus interest (6% in dollars or 18.5% in pesos), social benefits, legal expenses and fees (25% of the award) against InspireMD Ltd. and InspireMD GmbH. The Company settled with the plaintiff in the amount of $80,000 plus $20,000 for legal fees, which was approved by the Labor Court and paid by the Company in March 2016. The Company received written communication from a distributor to provide unspecified compensation for pre-paid goods subject to the voluntary field action. After considering the views of its legal counsel as well as other factors, the Company’s management believes that there is a reasonably possible likelihood of a loss from any related future proceedings would range from a minimal amount up to 1,075,000 Euros. On April 26, 2016 the Company received a suit seeking damages from the Company amounting to $2.2 million in cash and unspecified compensation in equity in connection with certain finders’ fees. The Company’s management, after considering the views of its legal counsel as well as other factors, is of the opinion that a loss to the Company is neither probable nor in an amount or range of loss that is estimable. In July 2016, a service provider filed a suit seeking damages from the Company’s subsidiary amounting to $1,967,822 The Company’s management, after considering the views of its legal counsel as well as other factors, is of the opinion that a loss to the Company is neither probable nor in an amount or range of loss that is estimable.

Equity

Equity	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Equity	NOTE 10 - EQUITY a. Share capital The Company’s common shares are listed on the NYSE MKT. On September 30, 2015, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse stock split of its common stock, par value $0.0001 per share , effective as of October 1, 2015, which decreased the number of issued and outstanding shares of common stock and restricted shares of common stock from 3.1 million shares to 0.3 million shares. The Company’s authorized common stock was decreased from 125 million shares to 50 million shares. On May 25, 2016 the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the Company’s number of authorized shares of common stock from 50 million to 150 million. On September 28, 2016, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-twenty five reverse stock split of its common stock, par value $0.0001 per share , effective as of October 7, 2016, which decreased the number of issued and outstanding shares of common stock and restricted shares of common stock from 35.7 million shares to 1.4 million shares. Accordingly, as of December 31, 2016, the Company has authorized 155,000,000 shares of capital stock, par value $0.0001 per share, of which 150,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock. All related share and per share data have been retroactively applied to the financial statements and their related notes for all periods presented. On March 9, 2015, the Company sold 137,481 shares of its common stock and warrants to purchase 137,481 shares of common stock in a registered direct offering. Each purchaser received a warrant to purchase one share of common stock for each share of common stock that it purchased in the offering. The warrants, which are classified as equity, are exercisable immediately and have a term of exercise of 5 years from the date of issuance and an exercise price of $137.5. This offering resulted in net proceeds to the Company of approximately $12.4 million after deducting placement agent fees and other offering expenses. On January 26, 2016 the Company entered into option cancellation and release agreements with the Optionholders. See Note 10a. On March 21, 2016, the Company sold 117,327 shares of its common stock and warrants to purchase 58,668 shares of common stock in concurrent underwritten public offering and private placement (the “March 2016 Offering”). The common stock was sold at a price of $14.75 per share and each purchaser received a warrant to purchase one half of one share of common stock for each share of common stock that it purchased in the March 2016 Offering. The warrants, which are classified as equity, are exercisable immediately and have a term of exercise of 5 years from the date of issuance and an exercise price of $14.75. The March 2016 Offering resulted in gross proceeds to the Company of approximately $1.7 million ($1.4 million after deducting underwriting discount, placement agent fees and other offering expenses). In connection with the March 2016 Offering, on March 21, 2016, the Company issued to the underwriter and placement agent five-year warrants to purchase up to 5,867 shares of common stock at an exercise price of $18.44 per share. The warrants, which are classified as equity, are exercisable at any time during the period commencing six months following the date of issuance and ending five years from the date of issuance. On July 7, 2016, the Company closed a public offering of 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up to 1,769,696 shares of common stock (the “July 2016 Offering”). Each share of Series B Convertible Preferred Stock and the accompanying warrants were sold at a price of $33.00. Each share of Series B Convertible Preferred Stock is convertible into 4 shares of common stock reflecting a conversion price equal to $8.25 per share. The holders of Series B Convertible Preferred Stock will be entitled to receive cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion. The Series B Convertible Preferred Stock will automatically convert into shares after five years from issuance. Additionally, holders of the shares may elect to convert at anytime. The Series B Convertible Preferred Stock has certain anti-dilution provisions. In addition, the Series B Convertible Preferred Stock is subject to provisions providing for make-whole payments, pursuant to which, if the Series B Convertible Preferred Stock is converted into shares of common stock at any time prior to the fifth anniversary of the date of issuance, the holders will receive all of the dividends that, but for the early conversion, would have otherwise accrued on the applicable shares of Series B Convertible Preferred Stock being converted for the period commencing on the conversion date and ending on the fifth anniversary of the date of issuance, less the amount of all prior dividends paid on such converted Series B Convertible Preferred Stock before the date of conversion. The warrants are exercisable immediately and have a term of exercise of five years from the date of issuance and have an exercise price of $5.00 per share of common stock. The Company received gross proceeds of approximately $14.6 million from the July 2016 Offering, before deducting placement agent fees and offering expenses payable by the Company. For accounting purposes, the Company analyzed the classification of the Series B Convertible Preferred Stock, including whether the embedded conversion options should be bifurcated. As the Series B Convertible Preferred Stock is not redeemable, and the host contract was determined to be akin to equity, the entire instrument was classified as equity. The Company has also concluded that the warrants accompanying Series B Convertible Preferred Stock are classified as equity, since the warrants bear a fixed conversion ratio and all other criteria for equity classification have been met. During the year ended December 31, 2016, 130,903 shares of Series B Convertible Preferred Stock were converted into 916,321 shares of common stock. Following the closing of the July 2016 Offering, pursuant to a warrant agreement (see Note 4), the Company issued to a lender warrants to purchase 38,691 shares of common stock . As of December 31, 2016 the Company issued total of 2,029,912 warrants to purchase 2,029,912 shares of common stock. b. Share-Based Compensation 1) On March 28, 2011, the board of directors and stockholders of the Company adopted and approved the InspireMD, Inc. 2011 UMBRELLA Option Plan (the “Umbrella Plan”) which expires on March 27, 2021. Under the Umbrella Plan, as subsequently amended, the Company reserved 20,000 shares of common stock as awards to employees, consultants, and service providers. As of December 31, 2016, the Company had 1,694 shares of common stock available for future issuance under the plans as described above. On December 16, 2013, the board of directors and stockholders of the Company adopted and approved the 2013 Plan. Under the 2013 Plan, the Company initially reserved 20,000 shares of common stock for awards to employees, officers, directors, consultants, and service providers. On September 9, 2015, May 24, 2016 and September 28, 2016, the stockholders approved an amendment to the 2013 Plan to increase the number of shares of common stock available for issuance pursuant to awards under the 2013 Plan by 18,800, 400,000 and 252,000 shares of common stock, respectively, to a total of 690,800 shares of common stock. As of December 31, 2016, the Company reserved 233,189 shares of common stock available for future issuance under the plans as described above. The 2013 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and other awards, which may be granted singly, in combination, or in tandem. The 2013 Plan is administered by the Company’s compensation committee. In 2004, Section 409A was added to the U.S. Internal Revenue Code of 1986, as amended (the “Code”) to regulate all types of deferred compensation. Certain performance awards, stock options, stock appreciation rights, restricted stock units, and certain types of restricted stock are subject to Section 409A of the Code. Pursuant to the current Section 102 of the Israeli Tax Ordinance, which came into effect on January 1, 2003, options may be granted through a trustee (i.e., Approved 102 Options) or not through a trustee (i.e., Unapproved 102 Options). As a result of an election made by the Company under Section 102 of the Income Tax Ordinance, the Company will not be allowed to claim as an expense for tax purposes in Israel the amounts credited to the employee as capital gains to the grantees, although it will generally be entitled to do so in respect of the salary income component (if any) of such awards when the related tax is paid by the employee. 2) During the years ended December 31, 2016 and 2015, the Company granted stock options to the CEO, employees and directors to purchase a total of 328,698 and 8,599 shares of the Company’s common stock,respectively. The options have exercise prices ranging from $1.86-$12.5 and $42.5-$207.5 per share, respectively, which were the fair market value of the company’s common stock on the date of each respective grant. The fair value of the above options, using the Black-Scholes and the Monte-Carlo option pricing models, was approximately $1,023,000 and $660,000, respectively. Of the 328,698 stock options granted in 2016, 161,025 options are subject to a three-year vesting period with one-third of such awards vesting each year, 32,000 options are subject to a two-year vesting period with one-half of such awards vesting each year, 83,941 options are subject to a one-year vesting period, 28,331 options are fully vested as of their grant date and the remaining options are subject to certain market and performance conditions. Of the 8,599 stock options granted in 2015, 4,320 options are fully vested as of their grant date and the remaining options are subject to a three-year vesting period with one-third of such awards vesting each year. 3) During the year ended December 31, 2016 and 2015, the Company granted to the CEO, employees and directors 129,825 and 7,866 restricted shares of the Company’s common stock, respectively. The fair value of these restricted shares was approximately $545,000 and $1,157,000. Of the 129,825 restricted shares granted during the year ended December 31, 2016, 70,500 restricted shares are subject to a one-year vesting period and the remaining restricted shares are subject to a three-year vesting period, with one-third of such awards vesting each year. Of the 7,866 restricted shares granted during the year ended December 31, 2015, 1,732 restricted shares are subject to a one-year vesting period, 370 restricted shares are fully vested as of their grant date and are subject to a 6 month lock up period, 2,553 restricted shares are fully vested as of their grant date, 1,330 restricted shares are subject to a six-month vesting period and 1,881 restricted shares are subject to a three-year vesting period, with one-third of such awards vesting each year. 4) The following table summarizes information about warrants and share options to employees: Year ended December 31 2016 2015 Number of warrants and options Weighted average exercise price Number of warrants and options Weighted average exercise price Outstanding - beginning of period 28,548 $ 752.5 21,463 $ 1002.5 Granted 328,698 4.57 8,599 132.5 Forfeited (20,861 ) 689.47 (1,514 ) 767 Exercised (153 ) - Outstanding -end of period 336,232 $ 25.48 28,548 $ 752.5 Exercisable at the end of the period 51,275 $ 145.35 13,792 $ 1,159.25 5) The following table summarizes information about warrants and share options to non-employees: Year ended December 31 2016 2015 Number of warrants and options Weighted average exercise price Number of warrants and options Weighted average exercise price Outstanding - beginning of period 5,372 $ 1,134 5,597 $ 1,120 Granted - - - - Forfeited (3,722 ) 1,278.55 (225 ) 766.75 Exercised (147 ) - Outstanding - end of period 1,503 $ 890.42 5,372 $ 1,134.25 Exercisable at the end of the period 1,485 $ 886.28 5,356 $ 1,134 6) The following table summarizes information about restricted shares to employees: Year ended December 31 2016 2015 Number of restricted shares Outstanding - beginning of period 5,889 4,103 Granted 129,825 7,866 Forfeited (1,266 ) (406 ) Vested (3,999 ) (5,674 ) Outstanding - end of period 130,449 5,889 7) The following table provides additional information about all warrants and options outstanding and exercisable: Outstanding as of December 31, 2016 Exercise price Warrants and options outstanding Weighted average remaining contractual life (years) Warrants and options exercisable $0-$1.86 45,823 9.76 382 $3.04-$3.25 143,400 4.68 - $4.75-$12.5 139,857 9.51 43,932 $42.5-$207.5 3,405 7.43 3,280 $557.5-$2,100 5,250 3.89 5,165 337,735 7.39 52,760 The weighted average of the remaining contractual life of total vested and exercisable warrants and options as of December 31, 2016 was 8.70 years. The aggregate intrinsic value of the total exercisable warrants and options as of December 31, 2016 was approximately $955. The weighted average fair value of warrants and options granted was approximately $3.11 and $77.75 for the years ended December 31, 2016 and 2015, respectively. The weighted average fair value of warrants and options granted was estimated using the Black-Scholes option-pricing model. 8) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the years ended December 31, 2016 and 2015: Year ended December 31 2016 2015 Expected life 5-6.5 years 5-6.5 years Risk-free interest rates 1.01%-2.06% 1.41%-1.71% Volatility 85.8%-91.03% 62.68%-71.12% Dividend yield 0 % 0 % The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life). Until December 31, 2015, the Company estimated forfeitures based on its employment termination history. Beginning January 1, 2016, the Company adopted ASU 2016-09 and elected to account for forfeitures as they occur. The annual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as both the exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from a blended volatility, based on its historical data and that of a peer group of public companies. 9) As of December 31, 2016, the total unrecognized compensation cost on employee and non-employee stock options and restricted shares, related to unvested stock-based compensation, amounted to approximately $1 million. This cost is expected to be recognized over a weighted-average period of approximately 0.83 years. This expected cost does not include the impact of any future stock-based compensation awards. 10) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: Year ended December 31 2016 2015 ($ in thousands) Cost of revenues $ 1 $ 8 Research and development 182 716 Sales and marketing (85 ) 179 General and administrative 880 2,145 Restructuring and impairment - 59 $ 978 $ 3,107

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Taxes on Income	NOTE 11 - TAXES ON INCOME: a. Tax laws applicable to the Company and its subsidiaries Taxation in the United States InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable corporate tax rate is 34%. Taxation in Israel In January 2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction of corporate tax rate in 2016 and thereafter, from 26.5% to 25%. In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%. However, the law also included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate will be 24% in 2017 and 23% in 2018 and thereafter. Taxation in Germany InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825% and trade tax rate of 17.15%. Taxation in UK InspireMD UK is taxed according to the tax laws in the UK. Accordingly, the applicable tax rate is a corporate tax rate of 20%. The Company closed InspireMD UK in 2015. b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”): InspireMD Ltd. has been granted a “Beneficiary Enterprises” status under the Investment Law including Amendment No. 60 thereof, which became effective in April 2005. The tax benefits derived from any such Beneficiary Enterprise relate only to taxable profits attributable to the specific program of investment to which the status was granted. The main benefit, to which InspireMD Ltd. is entitled, conditional upon the fulfilling of certain conditions stipulated by the above law, is a two-year exemption and eight years of a reduced tax rate of 10% to 25% from tax on income derived from beneficiary activities in facilities in Israel. The two-year exemption starts only when the Company starts to pay taxes after using all carryforward tax losses. The tax benefit period is twelve years from the year of election, which means that after a year of election, the two-year exemption and eight years of reduced tax rate can only be used within the next twelve years. The Company elected the year 2007, as a year of election and 2011 as an additional year of election. In the event of a distribution of tax-exempt income attributable to “Beneficiary Enterprises” as a cash dividend, the Company will be required to pay tax at a rate of 10% to 25% on the amount distributed, subject to certain conditions. In addition, dividends originating from income attributable to the “Beneficiary Enterprises” will be subject to a 15% withholding tax. Should InspireMD Ltd. derive income from sources other than the “Beneficiary Enterprises” during the period of benefits, such income shall be taxable at the regular corporate tax rate. 1) Conditions for entitlement to the benefits The entitlement to the above benefits is conditional upon InspireMD Ltd. fulfilling the conditions stipulated by the law, regulations published thereunder and the instruments of approval for the specific investments in approved assets. In the event of failure to comply with these conditions, the benefits may be cancelled and InspireMD Ltd. may be required to refund the amount of the benefits, in whole or in part, with the addition of interest. The Company opted not to apply for Preferred Enterprise status. c. Carry forward tax losses As of December 31, 2016, InspireMD Ltd. had a net carry forward tax loss of approximately $60 million. Under Israeli tax laws, the carry forward tax losses can be utilized indefinitely. The Company had a net carry forward tax loss of approximately $33 million. Under U.S. tax laws, the Company’s tax losses can be utilized two years back and twenty years forward. As such the Company’s carry forward tax losses will begin to expire on December 31, 2031. d. Loss before income taxes The components of loss before income taxes are as follows: Year ended December 31, 2016 2015 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (3,640 ) $ (6,131 ) Subsidiaries (4,820 ) (9,450 ) $ (8,460 ) $ (15,581 ) Current taxes on income The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the change in subsidiary tax rates and the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits. The changes in the valuation allowance for the year ended December 31, 2016 and 2015 were as follows: Year ended December 31, 2016 2015 ($ in thousands) Balance at the beginning of the year $ 28,970 $ 24,655 Changes during the year 712 4,315 Balance at the end of the year $ 29,682 $ 28,970 e. Accounting for Uncertain Tax position The Company has no uncertain tax positions as of December 31, 2016. A summary of open tax years by major jurisdiction is presented below: Jurisdiction Years U.S. 2013-2016 Israel 2013-2016 Germany 2011-2016 United Kingdom 2014-2015 f. Deferred income tax: December 31, 2016 2015 ($ in thousands) Short-term: Allowance for doubtful accounts $ 64 $ 74 Provision for vacation and recreation pay 34 105 98 179 Long-term: R&D expenses 459 1,326 Share-based compensation 4,027 3,737 Carry forward tax losses 25,053 23,674 Accrued severance pay, net 45 54 29,584 28,791 Less-valuation allowance (29,682 ) (28,970 ) $ - $ -

Supplementary Financial Stateme

Supplementary Financial Statement Information	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplementary Financial Statement Information	NOTE 12 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION: Balance sheets: a. Accounts receivable: The changes in “Allowance for doubtful accounts” during the years ended December 31, 2016 and 2015 are as follows: Year ended December 31, 2016 2015 ($ in thousands) Balance at beginning of period $ 346 $ 337 Additions during the period - 72 Deductions during the period - (49 ) Exchange rate differences (10 ) (14 ) Balance at end of period $ 336 $ 346 b. Inventories: December 31, 2016 2015 ($ in thousands) Finished goods $ 83 $ 301 Work in process 233 307 Raw materials and supplies 184 145 $ 500 $ 753 For the years ended December 31, 2016 and 2015, the Company recorded expenses for slow moving inventory in the amounts of $50,000 and $588,000, respectively. c. Accounts payable and accruals-other: December 31, 2016 2015 ($ in thousands) Employees and employee institutions $ 357 $ 412 Accrued vacation and recreation pay 137 377 Accrued clinical trials expenses 467 582 Provision for sales commissions 56 80 Accrued expenses 425 552 Other 5 3 $ 1,447 $ 2,006

Entity Wide Disclosure

Entity Wide Disclosure	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Entity Wide Disclosure	NOTE 13 - ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: Year ended December 31, 2016 2015 ($ in thousands) Germany $ 631 $ 519 Italy 382 415 Belarus 134 226 Brazil 57 238 Other 690 912 $ 1,894 $ 2,310 By product: Year ended December 31, 2016 2015 ($ in thousands) CGuard $ 1,147 $ 703 MGuard* 747 1,607 $ 1,894 $ 2,310 *Includes revenue from sales of both MGuard Prime and MGuard. By principal customers: Year ended December 31, 2016 2015 Customer A 28 % 9 % Customer B 13 % 7 % Customer C 7 % 10 % Customer D 5 % 11 % All tangible long lived assets are located in Israel.

Significant Accounting Polici22

Significant Accounting Policies (Polices)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates	a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, share based compensation and legal contingencies.
Functional Currency	b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.
Principles of Consolidation	c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and Cash Equivalents	d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents.
Concentration of Credit Risk and Allowance for Doubtful Accounts	e. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable are derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable- Trade”.
Inventory	f. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or market value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventories and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.
Property, Plant and Equipment	g. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements.
Impairment in Value of Long-lived Assets	h. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized and the assets would be written down to their estimated fair values, based on expected future discounted cash flows.
Revenue Recognition	i. Revenue recognition Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer and collection is reasonably assured. The Company recognizes revenue net of value added tax (VAT).
Research and Development Costs	j. Research and development costs Research and development costs are charged to the statement of operations as incurred.
Share-based Compensation	k. Share-based compensation Employee option awards are classified as equity awards and accounted for using the grant-date fair value method. The fair value of share-based awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period, net of estimated forfeitures. Until December 31, 2015, the Company estimated forfeitures based on historical experience and anticipated future conditions. Beginning on January 1, 2016, the Company adopted Accounting Standards Update (“ASU”) 2016-09 and and elected to account for forfeitures as they occur. See Note 2s4. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach. In addition, certain share-based awards of the Company are market and performance based and dependent upon achieving certain goals. With respect to performance based awards, the Company estimates the expected pre-vesting award probability that the performance conditions will be achieved. The Company only recognizes expense for those shares that are expected to vest.
Uncertain Tax Positions	l. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses -net”.
Deferred Income Taxes	m. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.
Advertising	n. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $0.1 million and $0.2 million for the years ended December 31, 2016 and 2015, respectively.
Net Loss Per Share	o. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock by the weighted average number of shares of common stock outstanding during the period. For the year ended December 31, 2016 the basic and diluted net loss per also included 602,614 weighted average shares of common stock issuable to holders of Series B Convertible Preferred Stock (since the conversion is based only on the passage of time – see Note 10a). The calculation of diluted net loss per share excludes potential share issuances of common stock upon the exercise of share options, warrants, restricted stocks and placement agent unit as the effect is anti-dilutive. The total number of shares of common stock related to outstanding options, warrants, restricted stocks and placement agent unit excluded from the calculations of diluted loss per share were 2,668,117 and 200,194 for the years ended December 31, 2016 and 2015, respectively.
Segment Reporting	p. Segment reporting The Company has one operating and reportable segment.
Fair Value Measurement	q. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Recently Adopted and Issued Accounting Pronouncements	s. Recently adopted and issued accounting pronouncements 1) In April, 2015, the Financial Accounting Standards Board (“FASB”) ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” The new guidance requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The new guidance does not affect the recognition and measurement of debt issuance costs. The new guidance became effective during the first quarter of 2016 and was applied on a retrospective basis. As of December 31, 2016 and December 31, 2015, $35,000 and $85,000, respectively were deducted from the carrying value of the “Current maturity of loan” in the consolidated balance sheets. 2) In May 2014, the FASB issued Accounting Standards Codification (“ASC”) 606, Revenue from contracts with customers. The objective of the new revenue standard is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. The revenue standard contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services, based on a five step model that includes the identification of the contract with the customer and the performance obligations in the contract, determination of the transaction price, allocation of the transaction price to the performance obligations in the contract and recognizing revenue when (or as) the entity satisfies a performance obligation. The revenue standard is effective for annual periods beginning on or after December 15, 2017. The Company expected that the adoption of this standard will not have a material impact on its consolidated financial statements. 3) On July 22, 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out and the retail inventory method are not impacted by the new guidance. The new guidance will be effective for public business entities in fiscal years beginning after December 15, 2016, including interim periods within those years. Prospective application is required. Early adoption is permitted as of the beginning of an interim or annual reporting period. The adoption of this standard is not expected to have a material impact on its consolidated financial statements. 4) In March 2016, the FASB issued ASU 2016-09 – Improvements to Employee Share Based Payment Accounting which simplifies certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. This ASU is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not yet been issued, and all amendments in the ASU that apply must be adopted in the same period. The Company adopted the update during the quarter ended December 31, 2016, and has retroactively applied the guidance effective as of January 1, 2016. The Company elected to account for forfeitures as they occur rather than estimate expected forfeitures which resulted in a cumulative-effect adjustment to retained earnings as of the beginning of the current period of $457,000. Certain amounts or ratios for 2016 interim periods have been restated to reflect the adoption of this new guidance. Adoption of this update does not affect the Company’s total equity or book value per share. 5) In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230) Restricted Cash”. The new guidance requires that the reconciliation of the beginning-of-period and end-of-period amounts shown in the statement of cash flows include restricted cash and restricted cash equivalents. If restricted cash is presented separately from cash and cash equivalents on the balance sheet, companies will be required to reconcile the amounts presented on the statement of cash flows to the amounts on the balance sheet. Companies will also need to disclose information about the nature of the restrictions. The guidance is effective for annual an interim reporting periods beginning after December 15, 2017, and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. 6) In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows Topic 230: Classification of Certain Cash Receipts and Cash Payments.” ASU No. 2016-15 issued guidance to clarify how certain cash receipts and cash payments should be presented in the statement of cash flows. ASU 2016-15 is effective for annual and interim reporting periods beginning on or after December 15, 2017 and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. 7) In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The new standard is effective for annual periods and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance. 8) In February 2016, the FASB issued ASU 2016-02, Leases, which requires to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The accounting standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company expected that the adoption of this standard will not have a material impact on its consolidated financial statements.

Restructuring and Impairment (T

Restructuring and Impairment (Tables)	12 Months Ended
	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Impairment	Year ended December 31, 2015 ($ in thousands) Employee termination costs (1) 305 Lease settlement (2) 101 Total restructuring $ 406 Impairment of royalties buyout (3) 576 Total restructuring and impairment $ 982 During the first quarter of 2015, the board of directors approved to curtail developing and promoting our bare metal stent platform and implementing another cost reduction/focused spending plan. The plan has four components: (i) reducing headcount; (ii) limiting the focus of clinical and development expenses to only carotid and neurovascular products; (iii) limiting sales and marketing expenses primarily to those related to the CGuard EPS stent launch; and (iv) reducing all other expenses (including conferences, travel, promotional expenses, executive cash salaries, director cash fees, rent, etc.). (1) During the year ended December 31, 2015, the company incurred $305,000 of costs associated with reducing the Company’s headcount. (2) On November 5, 2015, the Company entered into a second amendment (the “Second Lease Amendment”) to the lease agreement for its facilities in the U.S. Pursuant to the Second Lease Amendment and effective January 1, 2016, the Company agreed to reduce its leased space and surrender the released premises. The Company also agreed to pay transaction costs and settlement amount of $101,000. (3) During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	December 31, 2016 2015 ($ in thousands) Cost: Computer equipment $ 227 $ 221 Office furniture and equipment 107 104 Machinery and equipment 1,001 961 Leasehold improvements 143 143 1,478 1,429 Less - accumulated depreciation and amortization (1,099 ) (957 ) Net carrying amount $ 379 $ 472

Related Parties Transactions (T

Related Parties Transactions (Tables)	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Schedule of Balances with Related Parties	December 31, 2016 2015 ($ in thousands) Current liabilities: Other accounts payable $ 77 $ 132
Schedules of Transactions with Related Parties	Year ended December 31, 2016 2015 ($ in thousands) Compensation expenses (including share based compensation) $ 1,499 $ 1,892

Commitments and Contingent Li26

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Obligations	As of December 31, 2016, the aggregate future minimum lease obligations for office rent under non-cancelable operating lease agreements are as follows: ($ in thousands) Year Ended December 31: 2017 $ 326 2018 276 $ 602

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Warrants and Share Options	Year ended December 31 2016 2015 Number of warrants and options Weighted average exercise price Number of warrants and options Weighted average exercise price Outstanding - beginning of period 28,548 $ 752.5 21,463 $ 1002.5 Granted 328,698 4.57 8,599 132.5 Forfeited (20,861 ) 689.47 (1,514 ) 767 Exercised (153 ) - Outstanding -end of period 336,232 $ 25.48 28,548 $ 752.5 Exercisable at the end of the period 51,275 $ 145.35 13,792 $ 1,159.25 Year ended December 31 2016 2015 Number of warrants and options Weighted average exercise price Number of warrants and options Weighted average exercise price Outstanding - beginning of period 5,372 $ 1,134 5,597 $ 1,120 Granted - - - - Forfeited (3,722 ) 1,278.55 (225 ) 766.75 Exercised (147 ) - Outstanding - end of period 1,503 $ 890.42 5,372 $ 1,134.25 Exercisable at the end of the period 1,485 $ 886.28 5,356 $ 1,134
Schedule of Information About Restricted Shares to Employees	Year ended December 31 2016 2015 Number of restricted shares Outstanding - beginning of period 5,889 4,103 Granted 129,825 7,866 Forfeited (1,266 ) (406 ) Vested (3,999 ) (5,674 ) Outstanding - end of period 130,449 5,889
Schedule of Warrants and Options Outstanding and Exercisable	Outstanding as of December 31, 2016 Exercise price Warrants and options outstanding Weighted average remaining contractual life (years) Warrants and options exercisable $0-$1.86 45,823 9.76 382 $3.04-$3.25 143,400 4.68 - $4.75-$12.5 139,857 9.51 43,932 $42.5-$207.5 3,405 7.43 3,280 $557.5-$2,100 5,250 3.89 5,165 337,735 7.39 52,760
Schedule of Assumptions Used in Fair Value of Options Granted to Employees	Year ended December 31 2016 2015 Expected life 5-6.5 years 5-6.5 years Risk-free interest rates 1.01%-2.06% 1.41%-1.71% Volatility 85.8%-91.03% 62.68%-71.12% Dividend yield 0 % 0 %
Schedule of Allocation of Total Share-based Compensation Expense	Year ended December 31 2016 2015 ($ in thousands) Cost of revenues $ 1 $ 8 Research and development 182 716 Sales and marketing (85 ) 179 General and administrative 880 2,145 Restructuring and impairment - 59 $ 978 $ 3,107

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of Loss Before Income Taxes	Year ended December 31, 2016 2015 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (3,640 ) $ (6,131 ) Subsidiaries (4,820 ) (9,450 ) $ (8,460 ) $ (15,581 )
Schedule of Changes in the Valuation Allowance	Year ended December 31, 2016 2015 ($ in thousands) Balance at the beginning of the year $ 28,970 $ 24,655 Changes during the year 712 4,315 Balance at the end of the year $ 29,682 $ 28,970
Schedule of Open Tax Years by Major Jurisdiction	Jurisdiction Years U.S. 2013-2016 Israel 2013-2016 Germany 2011-2016 United Kingdom 2014-2015
Schedule of Deferred Income Tax	December 31, 2016 2015 ($ in thousands) Short-term: Allowance for doubtful accounts $ 64 $ 74 Provision for vacation and recreation pay 34 105 98 179 Long-term: R&D expenses 459 1,326 Share-based compensation 4,027 3,737 Carry forward tax losses 25,053 23,674 Accrued severance pay, net 45 54 29,584 28,791 Less-valuation allowance (29,682 ) (28,970 ) $ - $ -

Supplementary Financial State29

Supplementary Financial Statement Information (Tables)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Allowance for Doubtful Accounts	Year ended December 31, 2016 2015 ($ in thousands) Balance at beginning of period $ 346 $ 337 Additions during the period - 72 Deductions during the period - (49 ) Exchange rate differences (10 ) (14 ) Balance at end of period $ 336 $ 346
Schedule of Inventories	December 31, 2016 2015 ($ in thousands) Finished goods $ 83 $ 301 Work in process 233 307 Raw materials and supplies 184 145 $ 500 $ 753
Schedule of Accounts Payable and Accruals-other	December 31, 2016 2015 ($ in thousands) Employees and employee institutions $ 357 $ 412 Accrued vacation and recreation pay 137 377 Accrued clinical trials expenses 467 582 Provision for sales commissions 56 80 Accrued expenses 425 552 Other 5 3 $ 1,447 $ 2,006

Entity Wide Disclosure (Tables)

Entity Wide Disclosure (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Schedule of Revenues are Attributed to Geographic Areas	Year ended December 31, 2016 2015 ($ in thousands) Germany $ 631 $ 519 Italy 382 415 Belarus 134 226 Brazil 57 238 Other 690 912 $ 1,894 $ 2,310
Schedule of Revenues are Attributed to Geographic Areas By Product	Year ended December 31, 2016 2015 ($ in thousands) CGuard $ 1,147 $ 703 MGuard* 747 1,607 $ 1,894 $ 2,310 *Includes revenue from sales of both MGuard Prime and MGuard.
Schedule of Revenues are Attributed to Geographic Areas Principal Customers	Year ended December 31, 2016 2015 Customer A 28 % 9 % Customer B 13 % 7 % Customer C 7 % 10 % Customer D 5 % 11 %

Significant Accounting Polici31

Significant Accounting Policies (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)Numbershares	Dec. 31, 2015USD ($)shares
Description of methodology used for computing depreciation	straight-line method
Description of uncertain tax benefits	Tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Advertising expense | $	$ 100	$ 200
Weighted average shares common stock issuable | shares	1,425,617	279,055
Number of antidilutive securities excluded from computation of earnings per share amount | shares | shares	2,668,117	200,194
Number of operating segment | Number	1
Number of reportable segment | Number	1
Accounting Standards Update 2015-03 [Member]
Carrying value of current maturity of loan | $	$ 35	$ 85
Accounting Standards Update 2016-09 [Member]
Cumulative-effect adjustment to retained earnings | $	$ 457
Series B Convertible Preferred Stock [Member]
Weighted average shares common stock issuable | shares	602,614
Computers And Other Electronic Equipment [Member]
Estimated useful life	3 years
Office Furniture And Equipment [Member] | Minimum [Member]
Estimated useful life	7 years
Office Furniture And Equipment [Member] | Maximum [Member]
Estimated useful life	15 years
Machinery And Equipment [Member]
Estimated useful life	7 years

Restructuring and Impairment -

Restructuring and Impairment - Schedule of Restructuring and Impairment (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Employee termination costs (1)	[1]		$ 305
Lease settlement (2)	[2]		101
Total restructuring			406
Impairment of royalties buyout (3)			576	[3]
Total restructuring and impairment			$ 982
[1]	During the year ended December 31, 2015, the company incurred $305,000 of costs associated with reducing the Company’s headcount.
[2]	On November 5, 2015, the Company entered into a second amendment (the “Second Lease Amendment”) to the lease agreement for its facilities in the U.S. Pursuant to the Second Lease Amendment and effective January 1, 2016, the Company agreed to reduce its leased space and surrender the released premises. The Company also agreed to pay transaction costs and settlement amount of $101,000.
[3]	During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents.

Property, Plant and Equipment33

Property, Plant and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation and amortization expenses	$ 142	$ 152

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property plant and equipment, gross	$ 1,478	$ 1,429
Less - accumulated depreciation and amortization	(1,099)	(957)
Net carrying amount	379	472
Computer Equipment [Member]
Property plant and equipment, gross	227	221
Office Furniture And Equipment [Member]
Property plant and equipment, gross	107	104
Machinery And Equipment [Member]
Property plant and equipment, gross	1,001	961
Leasehold Improvements [Member]
Property plant and equipment, gross	$ 143	$ 143

Liability for Employees Right35

Liability for Employees Right Upon Retirement (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Percentage of monthly salaries	8.33%
Severance expenses	$ 130	$ 211
Defined contribution plan expense	157	$ 213
Defined contribution plan expense estimated	$ 198

Loan (Details Narrative)

Loan (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Oct. 23, 2016	Jun. 13, 2016	Dec. 31, 2016	Mar. 21, 2016	Mar. 09, 2015
Debt instrument interest rate			10.00%
Future principal payment obligation of debt			$ 2,237
Minimum amount of fundraising in order to defer principal payments of loan		$ 10,000
Minimum amount of fundraising in order to calculate number of warrants			$ 7,500
Number of warrants to purchase of common shares			2,029,912	5,867
Warrants to exercise price				$ 18.44	$ 137.5
Lender [Member]
Number of warrants to purchase of common shares, value			$ 182,399
Lender [Member] | July 2016 Offering [Member]
Number of warrants to purchase of common shares			38,691
Warrants term			5 years
Warrants to exercise price			$ 4.71
Minimum [Member]
Increase decrease in term cost		500
Maximum [Member]
Increase decrease in term cost		$ 520
Loan and Security Agreement [Member]
Original aggregate principal amount	$ 10,000
Description of interest rate	The annual interest rate on the Loan is prime plus 4%
Debt instrument maturity date	Feb. 1, 2017
Description of repayment terms	The Company is permitted to prepay all or a portion of the Loan. However, any prepayments of the Loan will be subject to a penalty of (i) 2%, if the prepayment occurs within 12 months of the Loan being requested by the Company and InspireMD Ltd. (the “Advance Date”), (ii) 1%, if the prepayment occurs between 12 and 24 months after the Advance Date, and (iii) 0.5%, if the prepayment occurs more than 24 months after the Advance Date.
Unused borrowing capacity fee	$ 500
Loan and Security Agreement [Member] | Minimum [Member]
Debt instrument interest rate	10.50%

Related Parties Transactions (D

Related Parties Transactions (Details Narrative) - USD ($)	Aug. 01, 2016	Jun. 06, 2016	Jun. 02, 2016	Apr. 30, 2016	Jan. 26, 2016	Jan. 21, 2016	Jul. 25, 2016	Dec. 31, 2016	Dec. 31, 2015
Proceeds from equity offering								$ 15,000,000
Fair value of stock option								$ 526,000	$ 338,000
Option term								10 years
Value of options cancelled for unrecognized compensation cost
Vesting period								3 years
Market Cap Related Conditions [Member]
Fair value assumptions, dividend yield								0.00%
Fair value assumptions, expected term								10 years
Fair value assumptions, expected volatility								85.73%
Fair value assumptions, risk free interest rate								1.81%
Fair value of stock option								$ 96,000
Performance Conditions [Member]
Fair value assumptions, dividend yield								0.00%
Fair value assumptions, expected term								5 years 6 months
Fair value assumptions, expected volatility								85.81%
Fair value assumptions, risk free interest rate								1.25%
Fair value of stock option								$ 66,000
Minimum [Member]
Proceeds from equity offering								$ 25,000,000
Chief Executive Officer [Member]
Extended term		May 31, 2017
Chief Executive Officer [Member] | Maximum [Member]
Percentage of base salary		10.00%
New Director [Member]
Number of option granted				31,202
New Director And Vice Chairman [Member]
Number of option granted				7,801
Director [Member]
Number of option granted								134,232	5,555
Share based compensation, shares									4,320
Director [Member] | Tranche One [Member]
Number of option granted								82,500
Director [Member] | Tranche Two [Member]
Number of option granted								20,530
Director [Member] | Maximum [Member]
Exercise price for option granted, per share								$ 12.50	$ 195
Director [Member] | Minimum [Member]
Exercise price for option granted, per share								$ 3.04	$ 42.50
Chief Executive Officer [Member]
Percentage of base salary			100.00%
lump-sum retention bonus amount			$ 106,458
Restricted common stock shares percentage			2.00%
Number of restricted shares	70,500
Fair value assumptions, dividend yield	0.00%
Fair value assumptions, expected term	5 years
Fair value assumptions, expected volatility	87.29%
Fair value assumptions, risk free interest rate	1.22%
Fair value of stock option	$ 200,000							$ 1,023,000	$ 660,000
Fair value of restricted shares common stock	$ 300,000
Vesting period								3 years
Former Chief Executive Officer [Member]
Monthly salaries and related expenses						$ 18,750
Percentage of base salary paid in lump-sum payment						50.00%
Investor [Member]
Proceeds from equity offering			$ 5,000,000			$ 5,000,000
Optionholders [Member]
Number of option cancelled					16,910
Value of options cancelled for unrecognized compensation cost					$ 800,000
Fourth Amendment Employment Agreement [Member] | Chief Executive Officer [Member]
Percentage of base salary			50.00%			50.00%
Monthly salaries and related expenses						$ 18,750
Percentage of base salary paid in lump-sum payment			50.00%
Employment Agreement [Member] | Chief Executive Officer [Member]
Proceeds from equity offering							$ 5,000,000
Number of option granted							70,500
Exercise price							$ 4.75

Related Parties Transactions -

Related Parties Transactions - Schedule of Balances with Related Parties (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Related Party Transactions [Abstract]
Other accounts payable	$ 77	$ 132

Related Parties Transactions 39

Related Parties Transactions - Schedules of Transactions with Related Parties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Related Party Transactions [Abstract]
Compensation expenses (including share based compensation)	$ 1,499	$ 1,892

Commitments and Contingent Li40

Commitments and Contingent Liabilities (Details Narrative)	Apr. 26, 2016USD ($)	Jul. 31, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016EUR (€)	Dec. 31, 2012USD ($)
Rent expenses				$ 319,000	$ 383,000
Restructuring and impairment rent expenses					$ 101,000
Future minimum lease obligations				602,000
InspireMD GmbH [Member] | Former Service Provider [Member]
Maximum amount of claim							$ 193,378
Percentage of social benefits & legal expenses of awards							25.00%
Settlement amount			$ 80,000
Litigation settlement expense			$ 20,000
InspireMD GmbH [Member] | Former Service Provider [Member] | Euro [Member]
Maximum amount of claim | €						€ 1,075,000
InspireMD GmbH [Member] | Former Service Provider [Member] | Argentina Pesos Interest Rate [Member]
Percentage of interest rate							18.50%
InspireMD GmbH [Member] | Former Service Provider [Member] | USA Dollar Interest Rate [Member]
Percentage of interest rate							6.00%
InspireMD GmbH [Member] | Former Service Provider [Member]
Received cash on seeking damage	$ 2,200,000
Law suit seeking damages		$ 1,967,822
Motor Vehicles [Member]
Future minimum lease obligations				$ 6,000
US [Member]
Lease expiration				Oct. 31, 2017
IL [Member]
Lease expiration				Dec. 31, 2020
Lease expiration date description				The Subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2018 with an option to extend the agreement for two additional years until December 31, 2020 under the terms stipulated in the agreement.

Commitments and Contingent Li41

Commitments and Contingent Liabilities - Schedule of Future Minimum Lease Obligations (Details) $ in Thousands	Dec. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 326
2,018	276
Total	$ 602

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)	Aug. 01, 2016	Jul. 07, 2016	Mar. 21, 2016	Mar. 09, 2015	Dec. 31, 2016	Dec. 31, 2015	Oct. 07, 2016	Sep. 28, 2016	May 25, 2016	May 24, 2016	Sep. 30, 2015	Sep. 09, 2015	Dec. 16, 2013	Mar. 28, 2011
Common stock, per share					$ 0.0001	$ 0.0001
Common stock shares, issued					1,475,318	314,065
Common stock shares, outstanding					1,475,318	314,065
Common stock shares, authorized					150,000,000	50,000,000
Preferred stock, shares authorized					5,000,000	5,000,000
Number of common stock shares sold				137,481
Warrant terms				5 years
Warrant exercise price			$ 18.44	$ 137.5
Proceeds from sale of securities			$ 1,400,000	$ 12,400,000
Number of warrants to purchase common shares			5,867		2,029,912
Gross proceeds from offering, cost					$ 15,000,000
Stock option vested number of grant, shares					23,401
Number of common stock awards reserved for future issuance					1,694									20,000
Stock option granted					28,331
Stock option vesting period					3 years
Fair value of stock option					$ 526,000	$ 338,000
Weighted average of the remaining contractual life					8 years 8 months 12 days
Aggregate intrinsic value of the total exercisable warrants and options					$ 955,000
Weighted average fair value of warrants and options granted					$ 3.11	$ 77.75
Unrecognized compensation cost weighted-average period					9 months 29 days
Unvested stock-based compensation					$ 1,000,000
Three Year Vesting Period [Member]
Stock option granted					161,025
Stock option vested number of shares					4,320
Two Year Vesting Period [Member]
Stock option granted					32,000
One Year Vesting Period [Member]
Stock option granted					83,941
Board of Directors and Stockholders [Member] | 2013 Plan [Member]
Stock option vested number of grant, shares					690,800			252,000		400,000		18,800
Number of common stock awards reserved for future issuance					233,189								20,000
Chief Executive Officer [Member]
Stock option granted					328,698	8,599
Exercise price range lower limit					$ 1.86	$ 42.5
Exercise price range upper limit					$ 12.5	$ 207.5
Stock option vesting period					3 years
Fair value of stock option	$ 200,000				$ 1,023,000	$ 660,000
Employees and Directors [Member]
Stock option granted					328,698	8,599
Exercise price range lower limit					$ 1.86	$ 42.5
Exercise price range upper limit					$ 12.5	$ 207.5
Fair value of stock option					$ 1,023,000	$ 660,000
Capital Units [Member]
Common stock shares, authorized					155,000,000
Warrant [Member]
Number of common stock shares sold				137,481
Restricted Stock [Member]
Stock option granted					7,866
Restricted Stock [Member] | Three Year Vesting Period [Member]
Stock option granted					1,881
Restricted Stock [Member] | One Year Vesting Period [Member]
Stock option granted					70,500	1,732
Restricted Stock [Member] | 6 Month Lock Up Period [Member]
Stock option granted					370
Restricted Stock [Member] | 6 Month Vesting Period [Member]
Stock option granted					1,330
Restricted Stock [Member] | Chief Executive Officer [Member]
Stock option granted					129,825	7,866
Fair value of stock option					$ 545,000	$ 1,157,000
Restricted Stock [Member] | Employees and Directors [Member]
Stock option granted					129,825	7,866
Fair value of stock option					$ 545,000	$ 1,157,000
Series B Convertible Preferred Stock [Member]
Conversion stock shares converted					130,903
Convertible preferred stock shares issued					916,321
Underwritten Public Offering And Private Placement [Member]
Warrant terms			5 years
Number of common shares sold			117,327
Share price			$ 14.75
Underwritten Public Offering And Private Placement [Member] | Warrant [Member]
Warrant exercise price			$ 14.75
Proceeds from sale of securities			$ 1,700,000
Number of warrants to purchase common shares			58,668
July 2016 Offering [Member]
Number of warrants to purchase common shares					38,691
July 2016 Offering [Member] | Series B Convertible Preferred Stock [Member]
Number of common shares sold		442,424
Number of warrants to purchase common shares		1,769,696
Share price		$ 33
Conversion stock shares converted		4
Convertible preferred stock conversion price per share		$ 8.25
Cumulative dividend, percentage		15.00%
Exercise price		$ 5
Gross proceeds from offering, cost		$ 14,600,000
Minimum [Member]
Gross proceeds from offering, cost					$ 25,000,000
Secretary of State of Delaware A Certificate of Amendment [Member]
Common stock, per share								$ 0.0001			$ 0.0001
Common stock shares, issued											35,700,000
Common stock shares, outstanding											1,400,000
Secretary of State of Delaware A Certificate of Amendment [Member] | Minimum [Member]
Common stock shares, issued							1,400,000				300,000
Common stock shares, outstanding											300,000
Common stock shares, authorized									50,000,000		50,000,000
Secretary of State of Delaware A Certificate of Amendment [Member] | Minimum [Member] | Restricted Stock [Member]
Common stock shares, issued							1,400,000
Secretary of State of Delaware A Certificate of Amendment [Member] | Minimum [Member] | Restricted Stock [Member]
Common stock shares, issued											300,000
Common stock shares, outstanding											300,000
Secretary of State of Delaware A Certificate of Amendment [Member] | Maximum [Member]
Common stock shares, issued							35,700,000				3,100,000
Common stock shares, outstanding											3,100,000
Common stock shares, authorized									150,000,000		125,000,000
Secretary of State of Delaware A Certificate of Amendment [Member] | Maximum [Member] | Restricted Stock [Member]
Common stock shares, issued							35,700,000
Secretary of State of Delaware A Certificate of Amendment [Member] | Maximum [Member] | Restricted Stock [Member]
Common stock shares, issued											3,100,000
Common stock shares, outstanding											3,100,000

Equity - Schedule of Warrants a

Equity - Schedule of Warrants and Share Options (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee [Member]
Number of Options Outstanding - Beginning of Period	28,548	21,463
Number of Options Granted	328,698	8,599
Number of Options Forfeited	(20,861)	(1,514)
Number of Options Exercised	(153)
Number of Options Outstanding - End of Period	336,232	28,548
Number of Options Exercisable at the End of the Period	51,275	13,792
Weighted Average Exercise Price Outstanding - Beginning of Period	$ 752.5	$ 1,002.5
Weighted Average Exercise Price Granted	4.57	132.5
Weighted Average Exercise Price Forfeited	689.47	767
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Outstanding - End of Period	$ 25.48	$ 752.5
Weighted Average Exercise Price Exercisable at the End of the Period	145.35	1,159.25
Non Employee [Member]
Number of Options Outstanding - Beginning of Period	5,372	5,597
Number of Options Granted
Number of Options Forfeited	(3,722)	(225)
Number of Options Exercised	(147)
Number of Options Outstanding - End of Period	1,503	5,372
Number of Options Exercisable at the End of the Period	1,485	5,356
Weighted Average Exercise Price Outstanding - Beginning of Period	$ 1,134.25	$ 1,120
Weighted Average Exercise Price Granted
Weighted Average Exercise Price Forfeited	1,278.55	766.75
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Outstanding - End of Period	$ 890.42	$ 1,134.25
Weighted Average Exercise Price Exercisable at the End of the Period	886.28	1,134

Equity - Schedule of Informatio

Equity - Schedule of Information About Restricted Shares to Employees (Details) - Employee [Member] - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Number of Shares Outstanding	5,889	4,103
Number of shares Granted	129,825	7,866
Number of shares Forfeited	(1,266)	(406)
Number of shares Vested	(3,999)	(5,674)
Number of Shares Outstanding	130,449	5,889

Equity - Schedule of Warrants45

Equity - Schedule of Warrants and Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Warrant [Member]
Number of Shares Outstanding	337,735
Weighted average contractual term	7 years 4 months 21 days
Number of Options Exercisable at the End of the Period	52,760
Exercise Price One [Member]
Exercise price lower limit | $ / shares	$ 0
Exercise price upper limit | $ / shares	$ 1.86
Exercise Price One [Member] | Warrant [Member]
Number of Shares Outstanding	45,823
Weighted average contractual term	9 years 9 months 4 days
Number of Options Exercisable at the End of the Period	382
Exercise Price Two [Member]
Exercise price lower limit | $ / shares	$ 3.04
Exercise price upper limit | $ / shares	$ 3.25
Exercise Price Two [Member] | Warrant [Member]
Number of Shares Outstanding	143,400
Weighted average contractual term	4 years 8 months 5 days
Number of Options Exercisable at the End of the Period
Exercise Price Three [Member]
Exercise price lower limit | $ / shares	$ 4.75
Exercise price upper limit | $ / shares	$ 12.5
Exercise Price Three [Member] | Warrant [Member]
Number of Shares Outstanding	139,857
Weighted average contractual term	9 years 6 months 4 days
Number of Options Exercisable at the End of the Period	43,932
Exercise Price Four [Member]
Exercise price lower limit | $ / shares	$ 42.5
Exercise price upper limit | $ / shares	$ 207.5
Exercise Price Four [Member] | Warrant [Member]
Number of Shares Outstanding	3,405
Weighted average contractual term	7 years 5 months 5 days
Number of Options Exercisable at the End of the Period	3,280
Exercise Price Five [Member]
Exercise price lower limit | $ / shares	$ 557.5
Exercise price upper limit | $ / shares	$ 2.100
Exercise Price Five [Member] | Warrant [Member]
Number of Shares Outstanding	5,250
Weighted average contractual term	3 years 10 months 21 days
Number of Options Exercisable at the End of the Period	5,165

Equity - Schedule of Assumption

Equity - Schedule of Assumptions Used in Fair Value of Options Granted to Employees (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Dividend yield	0.00%	0.00%
Minimum [Member]
Expected life	5 years	5 years
Risk-free interest rates	1.01%	1.41%
Volatility	85.80%	62.68%
Maximum [Member]
Expected life	6 years 6 months	6 years 6 months
Risk-free interest rates	2.06%	1.71%
Volatility	91.03%	71.12%

Equity - Schedule of Allocation

Equity - Schedule of Allocation of Total Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Total share-based compensation expense	$ 978	$ 3,107
Cost of Revenues [Member]
Total share-based compensation expense	1	8
Research And Development [Member]
Total share-based compensation expense	182	716
Selling And Marketing [Member]
Total share-based compensation expense	(85)	179
General And Administrative Expense [Member]
Total share-based compensation expense	880	2,145
Restructuring And Impairment [Member]
Total share-based compensation expense		$ 59

Taxes on Income (Details Narrat

Taxes on Income (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Corporate tax rate	34.00%
Tax rate on income of beneficiary enterprises	15.00%
Net carry forward tax loss	$ 60,000
Operating loss carryforward expiration date	Dec. 31, 2031
2017 [Member]
Corporate tax rate	24.00%
2018 [Member]
Corporate tax rate	23.00%
Israel Tax Authority [Member]
Net carry forward tax loss	$ 33,000
Israel Tax Authority [Member] | Minimum [Member]
Corporate tax rate	25.00%
Revised tax rate on income of preferred enterprises	10.00%
Israel Tax Authority [Member] | Minimum [Member] | Economic Efficiency Law [Member]
Corporate tax rate	23.00%
Israel Tax Authority [Member] | Maximum [Member]
Corporate tax rate	26.50%
Revised tax rate on income of preferred enterprises	25.00%
Israel Tax Authority [Member] | Maximum [Member] | Economic Efficiency Law [Member]
Corporate tax rate	25.00%
Germany [Member] | Corporate Tax [Member]
Corporate tax rate	15.825%
Corporate trade tax rate	17.15%
UK [Member]
Corporate tax rate	20.00%

Taxes on Income - Schedule of C

Taxes on Income - Schedule of Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Loss before taxes on income	$ (8,460)	$ (15,581)
InspireMD [Member]
Loss before taxes on income	(3,640)	(6,131)
Subsidiaries [Member]
Loss before taxes on income	$ (4,820)	$ (9,450)

Taxes on Income - Schedule of50

Taxes on Income - Schedule of Changes in the Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 28,970	$ 24,655
Changes during the year	712	4,315
Balance at the end of the year	$ 29,682	$ 28,970

Taxes on Income - Schedule of O

Taxes on Income - Schedule of Open Tax Years by Major Jurisdiction (Details)	12 Months Ended
	Dec. 31, 2016
U.S. [Member] | Earliest Tax Year [Member]
Open Tax Year	2,013
U.S. [Member] | Latest Tax Year [Member]
Open Tax Year	2,016
Israel [Member] | Earliest Tax Year [Member]
Open Tax Year	2,013
Israel [Member] | Latest Tax Year [Member]
Open Tax Year	2,016
Germany [Member] | Earliest Tax Year [Member]
Open Tax Year	2,011
Germany [Member] | Latest Tax Year [Member]
Open Tax Year	2,016
United Kingdom [Member] | Earliest Tax Year [Member]
Open Tax Year	2,014
United Kingdom [Member] | Latest Tax Year [Member]
Open Tax Year	2,015

Taxes on Income - Schedule of D

Taxes on Income - Schedule of Deferred Income Tax (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Allowance for doubtful accounts	$ 64	$ 74
Provision for vacation and recreation pay	34	105
Deferred tax assets current	98	179
R&D expenses	459	1,326
Share-based compensation	4,027	3,737
Carry forward tax losses	25,053	23,674
Accrued severance pay, net	45	54
Deferred tax assets noncurrent	29,584	28,791
Less-valuation allowance	(29,682)	(28,970)	$ (24,655)
Deferred tax assets

Supplementary Financial State53

Supplementary Financial Statement Information (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Slow moving inventory expense	$ 50	$ 588

Supplementary Financial State54

Supplementary Financial Statement Information - Schedule of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance at beginning of period	$ 346	$ 337
Additions during the period		72
Deductions during the period		(49)
Exchange rate differences	(10)	(14)
Balance at end of period	$ 336	$ 346

Supplementary Financial State55

Supplementary Financial Statement Information - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 83	$ 301
Work in process	233	307
Raw materials and supplies	184	145
Total inventories	$ 500	$ 753

Supplementary Financial State56

Supplementary Financial Statement Information - Schedule of Accounts Payable and Accruals-other (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Employees and employee institutions	$ 357	$ 412
Accrued vacation and recreation pay	137	377
Accrued clinical trials expenses	467	582
Provision for sales commissions	56	80
Accrued expenses	425	552
Other	5	3
Total accounts payable and accruals-other	$ 1,447	$ 2,006

Entity Wide Disclosures - Sched

Entity Wide Disclosures - Schedule of Revenues are Attributed to Geographic Areas (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues	$ 1,894	$ 2,310
Germany [Member]
Revenues	631	519
Italy [Member]
Revenues	382	415
Belarus [Member]
Revenues	134	226
Brazil [Member]
Revenues	57	238
Other [Member]
Revenues	$ 690	$ 912

Entity Wide Disclosures - Sch58

Entity Wide Disclosures - Schedule of Revenues are Attributed to Geographic Areas by Product (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenue		$ 1,894	$ 2,310
CGuard [Member]
Segment Reporting Information [Line Items]
Revenue		1,147	703
MGuard [Member]
Segment Reporting Information [Line Items]
Revenue	[1]	$ 747	$ 1,607
[1]	Includes revenue from sales of both MGuard Prime and MGuard.

Entity Wide Disclosures - Sch59

Entity Wide Disclosures - Schedule of Revenues are Attributed to Geographic Areas Principal Customers(Details) - Sales [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Customer A [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	28.00%	9.00%
Customer B [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	13.00%	7.00%
Customer C [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	7.00%	10.00%
Customer D [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	5.00%	11.00%